CoChat

Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets.

Open access
Chi, Junpeng, Bi, Wenhua, Lou, Keyuan, Ma, Jian, Wu, Jitao, Cui, Yuanshan · 2024 · Sexual Medicine Reviews

The DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index, and 1 are not checked yet; 58 of the 163 sources its claims cite were checked for support.

Abstract

INTRODUCTION: Penile induration disease, commonly known as Peyronie's disease (PD), is a connective tissue disorder that affects the penis, leading to the development of fibrous plaques, penile curvature, and erectile dysfunction. PD is a common male reproductive system disease with a complex etiology involving multiple genes, signaling pathways, and different phenotypes. OBJECTIVES: The etiology and pathogenesis of PD remain poorly understood, hindering the development of effective treatment strategies. By understanding the underlying mechanisms of PD, we can pave the way for targeted therapies and improved patient outcomes. METHODS: We reviewed the epidemiology and pathophysiology of PD. We performed database searches on Google Scholar, PubMed, Medline, and Web of Science from inception to September 2023. The literature reviewed included priapism guidelines, review articles, current trial studies, and various literature related to PD. RESULTS: This article provides a comprehensive overview of the current research progress on the disease, focusing on its genetic factors, signaling pathways, cellular mechanisms, phenotypic manifestations, and therapeutic targets. It can help identify individuals at higher risk, aid in early detection and intervention, and provide insights into fibrosis and tissue remodeling. It can also reveal potential therapeutic targets, guide accurate diagnoses and treatment strategies, and address the impact of the disease on patients' quality of life. CONCLUSION: By integrating insights from genomics, molecular pathways, clinical phenotypes, and therapeutic potentials, our research aims to achieve a deeper and more comprehensive understanding of PD, propelling the field toward innovative strategies that enhance the lives of those affected by PD. The complex manifestations and pathogenesis of PD necessitate the use of multiple treatment methods for personalized care.

Verified 2026-11-19 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

This is a narrative review of Peyronie’s disease (PD) that synthesizes genetic, signaling-pathway, phenotypic, and therapeutic literature to explain why PD develops and how it might be better targeted. The paper argues that PD is multifactorial, driven by interacting genetic susceptibility, inflammation, fibrosis, and cellular remodeling pathways, and that current therapies remain limited for preventing fibrosis or reversing erectile dysfunction (ED).

Key findings

  • PD is described as affecting approximately 0.4% to 9% of the male population, with higher incidence in certain age groups.
  • The review identifies several candidate genetic factors and loci associated with PD, including COL1A1, COL3A1, COL1A2, ALMS1, TIMP1/TIMP2, MMP2/MMP9, and the WNT2 locus; it also cites chromosomal abnormalities in fibroblasts from PD plaques, including abnormalities in chromosomes 7, 8, 17, 18, and X and recurrent Y deletions.
  • Multiple signaling pathways are implicated in PD pathogenesis, especially TGF-β, Wnt/β-catenin, PDGF, NF-κB, and also JAK-STAT, MAPK, RhoA/ROCK, and Shh; these pathways converge on fibroblast activation, myofibroblast differentiation, ECM accumulation, and fibrosis.
  • The paper summarizes current therapies as imperfect: conservative treatments may help symptoms, but current therapy “does not effectively prevent penile fibrosis or reverse ED,” and newer approaches such as collagenase Clostridium histolyticum, verapamil, pentoxifylline, tadalafil, traction therapy, shockwave therapy, and PRP are discussed as promising but with limitations.

Methods

  • Narrative review of the epidemiology and pathophysiology of PD, aimed at integrating genomics, molecular pathways, phenotypic manifestations, and therapeutic targets.
  • Database searches were performed in Google Scholar, PubMed, Medline, and Web of Science from inception to September 2023.
  • The literature reviewed included guidelines, review articles, current trial studies, and other PD-related publications; the paper also draws on previously reported bioinformatic analyses and cited primary studies.

Limitations

  • The paper states that the etiology and pathogenesis remain poorly understood and that the precise interplay and relative contributions of the pathways are still points of contention.
  • It also notes that further research is needed to clarify pathway interactions and identify safe and effective therapeutic targets.
  • Evident from the text: this is a review, not a primary study, so its conclusions depend on the quality and scope of the cited literature rather than new patient-level data.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/sxmrev/qeae006

Cites

155 of 158 references verified2 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Possible signaling pathways in Peyronie's disease.
Figure 1 Possible signaling pathways in Peyronie's disease.CC-BY-NC · From the PDF

Verification

Claims the paper makes

44 Valid · 4 Not valid · 51 Not checked · 62 Own results and interpretations

76 more claims · 26 with their cited sources checked

Create a free account to see all 161 claims and to verify the 23 references still open.

See all claims — free account
  • Probably not a substantial claim. 34
  • The quote only partly states this claim. 3
  • It may state two separate claims as one. 56

Create a free account to see these claims.

Citations

Cites

Show all 158 references

Research works printed but not linked: 1

  1. Chung, 2020, Peyronie’s disease: what do we know and how do we treat it?, Can J Urol, 27, 11

Cited by

See all 14

Metadata

Authors
Chi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y.
Affiliations
  • Qingdao University (CN)
  • Weifang Chinese Medicine Hospital (CN)
Corresponding author
  • Wu, Jitao
  • Cui, Yuanshan
Venue
Sexual Medicine Reviews
Published
2024-03-07
Volume
12
Issue
3
Pages
477-490
ISSN
  • 2050-0513 (ISSN-L)
  • 2050-0521
OpenAlex
W4392603935
Cited by
14
References
154
Citations by year
2026: 7 · 2025: 5 · 2024: 2
FWCI
1.04
Type
journal article
Language
en
Open access
Locations
  • Sexual Medicine Reviews (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Shandong Natural Science Foundation (ZR2021LSW019)
  • National Nature Science Foundation of China (81870525, 82000649)
  • Taishan Scholars Program of Shandong Province (tsqn202306403, tsqn201909199)
Topics
  • Health Sciences › Medicine › Rheumatology › Dupuytren's Contracture and Treatments
  • Health Sciences › Medicine › Urology › Urological Disorders and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
Keywords
Peyronie's disease, penile fibrosis, penile curvature, erectile dysfunction, genetic susceptibility, signaling pathways, fibrosis, tissue remodeling, therapeutic target, disease phenotypes, pathogenesis, priapism
MeSH terms
Humans, Male, Penile Induration, Phenotype, Signal Transduction, Genomics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. https://app.cochat.ai/papers/10.1093/sxmrev/qeae006
The paper
Chi, J., Bi, W., Lou, K., Ma, J., Wu, J., & Cui, Y. (2024). Research advances in Peyronie's disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets. Sexual Medicine Reviews. https://doi.org/10.1093/sxmrev/qeae006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.